fingolimod
EMA adds warning label to Novartis’ MS treatment Gilenya
December 22, 2015Manufacturing and Production EMA, European Medicines Agency, FDA, Novartis, PML, basal cell carcinoma, fingolimod, gilenya
Drug safety regulators in Europe have said they will add warnings to the label and prescribing information of Gilenya (fingolimod), …
Novartis looks to new measure of Gilenya outcomes
October 8, 2015Research and Development fingolimod, gilenya, multiple sclerosis, relapsing multiple sclerosis
Novartis says a new analysis from two Phase III trials reinforces the long-term efficacy profile of its MS treatment Gilenya. …
Novartis MS drug scores positive late-stage trial result
April 21, 2015Research and Development, Sales and Marketing MS, Novartis, fingolimod, gilenya, multiple sclerosis
People with some of the most common forms of multiple sclerosis (MS) who are treated with Gilenya are less likely …
Novartis to highlight Gilenya data at neurology congress
April 13, 2015Sales and Marketing American Academy of Neurology, Novartis, fingolimod, gilenya
Novartis will be highlighting data for its multiple sclerosis drug Gilenya at this year’s American Academy of Neurology (AAN) annual …
NICE U-turn sees Gilenya MS pill recommended
March 16, 2012Sales and Marketing MS, NICE, UK, fingolimod, gilenya
NICE has changed its mind on Novartis’ multiple sclerosis pill Gilenya, and is now recommending the drug in a subgroup …
First oral MS pill approved in Europe
March 21, 2011Sales and Marketing MS, Novaris, fingolimod, first oral multiple sclerosis drug, gilenya, multiple sclerosis
Novartis’ Gilenya has become the first oral multiple sclerosis drug to be approved in Europe. Gilenya (fingolimod) is now licensed …
Merck Serono halts Movectro European licence application
February 18, 2011Medical Communications, Sales and Marketing Cladribine, MS, Merck KGaA, Merck Serono, Movectro, fingolimod, gilenya, multiple sclerosis
Merck Serono has withdrawn its European licence application for multiple sclerosis drug Movectro. Movectro (cladribine) is a new oral treatment …
Novartis MS drug steals march over Merck rival
January 24, 2011Sales and Marketing Cladribine, MS, Merck KGaA, Novartis, fingolimod, gilenya, multiple sclerosis
Novartis’ oral multiple sclerosis Gilenya could be on the European market in just three months after winning the backing of …
